Clinical Trials
131 trialsNCT07221149 2026-06-04
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06764771 2026-06-03
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT05568095 2026-06-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT07620574 2026-06-02
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Phase 3 Not yet recruiting
NCT07492680 2026-05-29
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT05176483 2026-05-27
STELLAR-002
Exelixis
Phase 1 Recruiting
NCT07431281 2026-05-27
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT07334119 2026-05-20
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT06948448 2026-05-18
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07432295 2026-05-14
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
Phase 2 Recruiting
NCT07563738 2026-05-04
TEADCO
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT05867121 2026-04-27
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT07219459 2026-04-27
GDFATHERHCC01
CatalYm GmbH
Phase 2 Recruiting
NCT06544655 2026-04-17
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT07527858 2026-04-14
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Gilead Sciences
Phase 2 Not yet recruiting
NCT05257590 2026-04-13
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT07392892 2026-04-13
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer
Phase 2/3 Recruiting
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03505320 2026-04-03
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT06504615 2026-04-03
METAGIO
Bristol-Myers Squibb
Active not recruiting
NCT04785820 2026-03-27
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Phase 2 Completed
NCT07176650 2026-03-16
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Shanghai Henlius Biotech
Phase 1 Recruiting
NCT06256328 2026-03-13
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT04900818 2026-03-05
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
Phase 1 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
Phase 1 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT05337137 2026-01-12
RELATIVITY-106
Bristol-Myers Squibb
Phase 1/2 Completed
NCT07328087 2026-01-09
COLONYVAQ™-CRC
Biogenea Pharmaceuticals Ltd.
Phase EARLY_PHASE1 Recruiting
NCT04567615 2026-01-08
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
Bristol-Myers Squibb
Phase 2 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04396821 2025-12-17
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT05322577 2025-12-05
FORTITUDE-103
Amgen
Phase 1/2 Active not recruiting
NCT06452329 2025-12-04
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Bristol-Myers Squibb
Completed
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03383458 2025-11-21
CheckMate 9DX
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04180371 2025-11-17
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
Phase 1/2 Active not recruiting
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT02817633 2025-10-28
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Tesaro, Inc.
Phase 1 Active not recruiting
NCT04208958 2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2 Completed
NCT05220722 2025-10-23
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
TriSalus Life Sciences, Inc.
Phase 1/2 Terminated
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05350501 2025-09-29
CLAUDE
Enterome
Phase 2 Terminated
NCT04278144 2025-09-15
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Phase 1/2 Terminated